BioSpace News Archive

According to the report, the global PCR & real-time PCR molecular market was valued over US$ 4.1 Bn in 2021.

The demand for high quality patient care is surging in the U.S. healthcare landscape.

According to Nova one advisor’s latest research report on the The global AI in Medical Imaging market gathered revenue around USD 20.18 billion by the end of 2030 and is estimated to expand at a modest CAGR of 36.9% during the prediction period 2022 to 2030.

According to Nova one advisor’s latest research report on the global Artificial Intelligence In Diagnostics market size was estimated at USD 580.3 billion in 2021 and is expected to surpass around USD 5.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 26.7% during the forecast period 2022 to 2030.

According to Nova one advisor’s latest research report on the global Artificial Intelligence in Genomics market size was estimated at USD 283.42 million in 2021 and is expected to surpass around USD 5,973 million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 40.32% during the forecast period 2022 to 2030.

According to Nova one advisor’s latest research report on the global Enterprise Artificial Intelligence market size was estimated at USD 11.9 billion in 2021 and is expected to surpass around USD 155.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 34.7% during the forecast period 2022 to 2030.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, reported financial results, and provided a business update for the second quarter ended June 30, 2022.

Bristol Myers Squibb and 2seventy bio, Inc. announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and refractory to the last regimen.

Kamada Ltd. today announced that it will release financial results for the second quarter and first half ended June 30, 2022, prior to the open of the U.S. financial markets on Wednesday, August 17, 2022.

TScan Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided business updates.